The administration of olanzapine and fluoxetine has synergistic effects on intracellular survival pathways in the rat brain

Journal of Psychiatric Research

Volumn 46, Issue 8, 2012, Pages 1029-1035

  Réus, Gislaine Z ^a   Abelaira, Helena M ^a   Agostinho, Fabiano R ^a   Ribeiro, Karine F ^a   Vitto, Marcelo F ^a   Luciano, Thais F ^a   De Souza, Claúdio T ^a   Quevedo, João ^a  

^a UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

Author keywords

Akt; BAD; Bcl 2; BDNF; CREB; Fluoxetine; Olanzapine

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; FLUOXETINE; FLUOXETINE PLUS OLANZAPINE; OLANZAPINE; PROTEIN BAD; PROTEIN BCL 2; PROTEIN KINASE B;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN; CELL SURVIVAL; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; DRUG POTENTIATION; HIPPOCAMPUS; INTRACELLULAR SIGNALING; MALE; MOOD DISORDER; NEUROPROTECTION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROMOTER REGION; RAT;

EID: 84863451702     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2012.04.016     Document Type: Article

References (66)

1. Agostinho F.R., Scaini G., Ferreira G.K., Jeremias I.C., Réus G.Z., Rezin G.T., et al. Effects of olanzapine, fluoxetine and olanzapine/fluoxetine on creatine kinase activity in rat brain. Brain Research Bulletin 2009, 80:337-340.
2. Agostinho F.R., Réus G.Z., Stringari R.B., Ribeiro K.F., Ferreira G.K., Jeremias I.C., et al. Olanzapine plus fluoxetine treatment alters mitochondrial respiratory chain activity in the rat brain. Acta Neuropsychiatrica 2011, 23:282-291.
3. Agostinho F.R., Réus G.Z., Stringari R.B., Ribeiro K.F., Ferraro A.K., Benedet J., et al. Treatment with olanzapine, fluoxetine and olanzapine/fluoxetine alters citrate synthase activity in rat brain. Neuroscience Letters 2011, 487:278-281.
4. Agostinho F.R., Réus G.Z., Stringari R.B., Ribeiro K.F., Pfaffenseller B., Stertz L., et al. Olanzapine plus fluoxetine treatment increases Nt-3 protein levels in the rat prefrontal cortex. Neuroscience Letters 2011, 497:99-103.
5. Aubry J.M., Schwald M., Ballmann E., Karege F. Early effects of mood stabilizers on the Akt/GSK-3β signaling pathway and on cell survival and proliferation. Psychopharmacology 2009, 205:419-429.
6. Bai O., Chlan-Fourney J., Bowen R., Keegan D., Li X.M. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. Journal of Neuroscience Research 2003, 71:127-131.
7. Bai O., Zhang H., Li X.M. Antipsychotic drugs clozapine and olanzapine upregulate bcl-2 mRNA and protein in rat frontal cortex and hippocampus. Brain Research 2004, 1010:81-86.
8. Basta-Kaim A., Budziszewska B., Jaworska-Feil L., Tetich M., Kubera M., LeŚkiewicz M., et al. Inhibitory effect of imipramine on the human corticotropin-releasing-hormone gene promoter activity operates through a PI3-K/AKT mediated pathway. Neuropharmacology 2005, 49:156-164.
9. Baumann B., Danos P., Krell D., Diekmann S., Leschinger A., Stauch R., et al. Reduced volume of limbic system-affiliated basal ganglia in mood disorders: preliminary data from a postmortem study. Journal of Neuropsychiatry and Clinical Neuroscience 1999, 11:71-78.
10. Belkhiri A., Dar A.A., Zaika A., Kelley M., El-Rifai W. Darpp promotes cancer cell survival by up-regulation of Bcl2 through Akt dependent mechanism. Cancer Research 2008, 68:395-403.
11. Ben-Shachar D., Karry R. Neuroanatomical pattern of mitochondrial complex I pathology varies between schizophrenia, bipolar disorder and major depression. PLoS One 2008, 3:3676.
12. Bobo W.V., Shelton R.C. Efficacy, safety and tolerability of Symbyax for acute-phase management of treatment-resistant depression. Expert Review of Neurotherapeutics 2010, 10:651-670.
13. Boer V., Alejel T., Beimesche S., Cierny I., Krause D., Knepel W., et al. CRE/CREB-driven up-regulation of gene expression by chronic social stress in CRE-luciferase transgenic mice: reversal by antidepressant treatment. PLoS One 2007, 2:431.
14. Bosch M.A., Artigas F., Adell A. Effects of acute olanzapine after sustained fluoxetina on extracellular monoamine levels in the rat medial prefrontal cortex. European Journal of Pharmacology 2005, 516:235-238.
15. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Annals of Biochemical 1976, 72:248-254.
16. Chiou S.H., Ku H.H., Tsai T.H., Lin H.L., Chen L.H., Chien C.S., et al. Moclobemide upregulated Bcl-2 expression and induced neural stem cell differentiation into serotoninergic neuron via extracellular regulated kinase pathway. British Journal of Pharmacology 2006, 148:587-598.
17. Cory S., Adams J.M. The Bcl2 family: regulators of the cellular life-or-death switch. Nature Reviews of Cancer 2002, 2:647-656.
18. Covington H.E., Vialou V., Nestler E.J. From synapse to nucleus: novel targets for treating depression. Neuropharmacology 2010, 58:683-693.
19. De Souza C.T., Gasparetti A.L., Pereira-da-Silva M., Araújo E.P., Carvalheira J.B., Saas M.J., et al. Peroxisome proliferator-activated receptor gamma coactivator-1-dependent uncoupling protein-2 expression in pancreatic islets of rats: a novel pathway for neural control of insulin secretion. Diabetologia 2003, 11:1522-1531.
20. Drzyzga L.R., Marcinowska A., Obuchowicz E. Antiapoptotic and neurotrophic effects of antidepressants: a review of clinical and experimental studies. Brain Research Bulletin 2009, 79:248-257.
21. Duman R.S., Monteggia L.M. A neurotrophic model for stress related mood disorders. Biological Psychiatry 2006, 59:1116-1127.
22. Emamian E.S., Hall D., Birnbaum M.J., Karayiorgou M., Gogos J.A. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nature Genetics 2004, 36:131-137.
23. Fattal O., Budur K., Vaughan A.J., Franco K. Review of the literature on major mental disorders in adult patients with mitochondrial diseases. Psychosomatics 2006, 47:1-7.
24. Gerber H.P., McMurtrey A., Kowalski J., Yan M., Keyt B.A., Dixit V., et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 30-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. The Journal of Biological Chemistry 1999, 273:30336-30343.
25. Hammonds M.D., Shim S.S. Effects of 4-week treatment with lithium and olanzapine on levels of brain-derived neurotrophic factor, B-cell CLL/lymphoma 2 and phosphorylated cyclic adenosine monophosphate response element-binding protein in the sub-regions of the hippocampus. Basic Clinical of Pharmacology and Toxicology 2009, 105:113-119.
26. Hatalski C.G., Baram T.Z. Stress-induced transcriptional regulation in the developing rat brain involves increased cyclic adenosine 3,5-monophosphateregulatory element binding activity. Molecular Endocrinology 1997, 11:2016-2024.
27. Hsiung S.C., Adlersberg M., Arango V., Mann J.J., Tamir H., Liu K.P. Attenuated 5-HT1A receptor signaling in brains of suicide victims: involvement of adenylyl cyclase, phosphatidylinositol 3-kinase, Akt and mitogen-activated protein kinase. Journal of Neurochemistry 2003, 87:182-194.
28. Huang E., Reichardt L.F. Trk receptors: roles in neuronal signal transduction. Annual Review of Biochemistry 2003, 2003(72):609-642.
29. Huang Y.Y., Peng C.H., Yang Y.P., Wu C.C., Hsu W.M., Wang H.J., et al. Desipramine activated Bcl-2 expression and inhibited lipopolysaccharide-induced apoptosis in hippocampus-derived adult neural stem cells. Trends in Pharmacological Science 2007, 104:61-72.
30. Jonas E.A., Hoit D., Hickman J.A., Brandt T.A., Polster B.M., Fannjiang Y., et al. Modulation of synaptic transmission by the BCL-2 family protein BCL-xL. Journal of Neuroscience 2003, 23:8423-8431.
31. Karege F., Perroud N., Burkhardt S., Schwald M., Ballmann E., La Harpe R., et al. Alteration in kinase activity but not in protein levels of protein kinase B and glycogen synthase kinase-3beta in ventral prefrontal cortex of depressed suicide victims. Biological Psychiatry 2007, 61:240-245.
32. Kessler R.C., Berglund P., Demler O., Jin R., Merikangas K.R., Walters E.E. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry 2005, 62:593-602.
33. Kock J.M., Hinze-Selch D., Stingele K., Huchzermeier C., Göder R., Seeck-Hirschner M., et al. Changes in CREB phosphorylation and BDNF plasma levels during psychotherapy of depression. Psychotherapy Psychosomatics 2009, 78:187-219.
34. Kosten T.A., Galloway M.P., Duman R.S., Russel D.S., D'Sa C. Repeated unpredictable stress and antidepressants differentially regulate expression of the Bcl-2 family of apoptotic genes in rat cortical, hippocampal, and limbic brain structures. Neuropsychopharmacology 2008, 33:1545-1558.
35. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
36. Lawlor M., Alessi D. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses?. Journal of Cell Science 2001, 114:2903-2910.
37. Lee J.G., Cho H.Y., Park S.W., Seo M.K., Kim Y.H. Effects of olanzapine on brain-derived neurotrophic factor gene promoter activity in SH-SY5Y neuroblastoma cells. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2010, 34:1001-1006.
38. Li P., Nijhawan D., Budihardjo I., Srinivasula S.M., Ahmad M., Alnemri E.S., et al. Cytochrome c and dATP dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997, 91:479-489.
39. Lindsten T., Zong W.-X., Thompson C.B. Defining the role of the Bcl-2 family of proteins in the nervous system. Neuroscientist 2005, 11:10-15.
40. Lonze B.E., Ginty D.D. Function and regulation of CREB family transcription factors in the nervous. Neuron 2002, 35:605-623.
41. Lu X.-H., Bradley R.J., Dwyer D.S. Olanzapine produces trophic effects in vitro and stimulates phopshorylation of Akt/PKB, ERK1/2 and the mitogen-activated protein kinase p38. Brain Research 2004, 1011:58-68.
42. Manji H.K., Drevets W.C., Charney D.S. The cellular neurobiology of depression. Nature Medicine 2001, 7:541-547.
43. Maragnoli M.E., Fumagalli F., Gennarelli M., Racagni G., Riva M.A., Fluoxetine, et al. Synergistic effects in the modulation of fibroblast growth factor 2 expression within the rat brain. Biological Psychiatry 2004, 55:1095-1102.
44. Myers K.M., Fiskum G., Liu Y., Simmens S.J., Bredesen D.E., Murphy A.N. Bcl-2 protects neural cells from cyanide/aglycemia-induced lipid oxidation, mitochondrial injury, and loss of viability. Journal of Neurochemistry 1995, 65:2432-2440.
45. Nakano M., Osada K., Misonoo A., Fujiwara K., Takahashi M., Ogawa Y., et al. Fluvoxamine and sigma-1 receptor agonists dehydroepiandrosterone (DHEA)-sulfate induces the Ser473-phosphorylation of Akt-1 in PC12 cells. Life Sciences 2010, 86:309-314.
46. Nibuya M., Nestler E.J., Duman R.S. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in the rat hippocampus. Journal of Neuroscience 1996, 16:2365-2372.
47. Ongur D., Drevets W.C., Price J.L. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proceedings of National Academic of Science USA 1998, 95:13290-13295.
48. Park S.W., Lee S.K., Kim J.M., Yoon J.S., Kim Y.H. Effects of quetiapine on the brain-derived neurotrophic factor expression in the hippocampus and neocortex of rats. Neuroscience Letters 2006, 402:25-29.
49. Pilar-Cuéllar F., Vidal R., Pazos A. Subchronic treatment with fluoxetine and ketanserin increases hippocampal brain-derived neurotrophic factor, β-catenin and antidepressant-like effects. Neuropharmacology 2012, 62:177-183.
50. Prabakaran S., Swatton J.E., Ryan M.M., Huffaker S.J., Huang J.T., Griffin J.L., et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Molecular Psychiatry 2004, 9:684-687.
51. Quiroz J.A., Gray A.N., Kato T., Manji H.K. Mitochondrially mediated plasticity in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology 2008, 33:2551-2565.
52. Réus G.Z., Stringari R.B., Kirsch T.R., Fries G.R., Kapczinski F., Roesler R., et al. Neurochemical and behavioural effects of acute and chronic memantine administration in rats: further support for NMDA as a new pharmacologicaltarget for the treatment of depression?. Brain Research Bulletin 2010, 81:585-589.
53. Réus G.Z., Stringari R.B., Ribeiro K.F., Ferraro A.K., Vitto M.F., Cesconetto P., et al. Ketamine plus imipramine treatment induces antidepressant-like behavior and increases CREB and BDNF protein levels and PKA and PKC phosphorylation in rat brain. Behavioural Brain Research 2011, 221:166-171.
54. Rogóz Z. Effects of co-treatment with mirtazapine and low doses of risperidone on immobility time in the forced swimming test in mice. Pharmacological Reports 2010, 62:1191-1196.
55. Rogóz Z., Shuza G., Legutko B. Repeated co-treatment with fluoxetine and amantadine induces brain-derived neurotrophic factor gene expression in rats. Pharmacological Reports 2008, 60:817-826.
56. Roman A., Rogóz Z., Kubera M., Nawrat D., Nalepa I. Concomitant administration of fluoxetine and amantadine modulates the activity of peritoneal macrophages of rats subjected to a forced swimming test. Pharmacological Reports 2009, 61:1069-1077.
57. Sheline Y.I., Wang P.W., Gado M.H., Csernansky J.G., Vannier M.W. Hippocampal atrophy in recurrent major depression. Proceedings of National Academic of Science USA 1996, 93:3908-3913.
58. Sheline Y.I., Gado M.H., Kraemer H.C. Untreated depression and hippocampal volume loss. American Journal of Psychiatry 2003, 160:1516-1518.
59. Shelton R.C. The return of fixed combinations in psychiatry: fluoxetine and olanzapine combination. Therapeutics and Clinical Risk Management 2006, 2:187-192.
60. Shelton R.C., Tollefson G.D., Tohen M., Stahl S., Gannon K.S., Acobs T.G., et al. A novel augmentation strategy for treating resistant major depression. American Journal of Psychiatry 2001, 158:131-134.
61. Shishkina G.T., Kalinina T.S., Berezova I.V., Dygalo N.N. Stress-induced activation of the brainstem Bcl-xL gene expression in rats treated with fluoxetine: correlations with serotonin metabolism and depressive-like behavior. British Journal of Pharmacology 2012, 165:1046-1057.
62. Tohen M., Case M., Trivedi M.H., Thase M.E., Burke S.J., Durell T.M. Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies. Clinical Psychiatry 2010, 71:451-462.
63. Vieta E., Locklear J., Gunther O., Ekman M., Miltenburger C., Chatterton M.L., et al. Treatment options for bipolar depression: a systematic review of randomized, controlled trials. Journal of Clinical Psychopharmacology 2010, 30:579-590.
64. Xu H., Steven R.J., Li X.M. Dose-related effects of chronic antidepressants on neuroprotective proteins BDNF, Bcl-2 and Cu/Zn-SOD in rat hippocampus. Neuropsychopharmacology 2003, 28:53-62.
65. Yang E., Zha J., Jockel J., Boise L.H., Thompson C.B., Korsmeyer S.J. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 1995, 80:285-291.
66. Yu H., Chen Z.Y. The role of BDNF in depression on the basis of its location in the neural circuitry. Acta Pharmacologica Sinica 2011, 32:3-11.